AIG Final Expense Insurance Fit Review for People With Diabetes

Research Snapshot

Why AIG Qualified for This Study

Questions This Section Answers

• Why did AIG qualify for this final expense insurance for people with diabetes study?
• How many AI platforms named AIG for diabetes-friendly final expense coverage?

AIG qualified because five of the seven included platforms named it during ranking discovery for a senior with diabetes seeking $15,000–$25,000 of permanent final expense coverage. The platforms that named AIG were anthropic, deepseek, grok, kimi, and perplexity; openai and google did not name it in the ranking stage. AIG's average listed rank was 5.4, with a best rank of 3 from perplexity.

The entity qualified on product relevance rather than proven diabetes underwriting. Corebridge markets a final expense whole life product family that includes both simplified-issue and Guaranteed Issue paths, which maps directly to the buyer's stated need for permanent coverage with a possible no-health-question fallback ^[6]. The platforms also treated AIG as a recognizable carrier with a national presence through Corebridge Financial, the entity that now holds the U.S. life and retirement business formerly associated with AIG ^[8].

Qualification does not mean the platforms agreed on fit. Four platforms rated AIG a "good" fit and three rated it "mixed," and the disagreement centered on whether the simplified-issue path is genuinely favorable for diabetes or merely available. That split is the central finding of this review.

The Product, Model, Plan, or Service Most Relevant to Final Expense Insurance for People With Diabetes

Questions This Section Answers

• Which AIG or Corebridge product should a senior with diabetes choose for $15,000 to $25,000 of final expense coverage?
• Is AIG's SimpliNow Legacy or Guaranteed Issue Whole Life the better fit for a diabetic buyer who wants day-one coverage?

The most relevant offering is Corebridge Final Expense Whole Life, sold in two main forms: a simplified-issue whole life product (marketed as SimpliNow Legacy or SIWL Direct) and a Guaranteed Issue Whole Life policy ^[10]. The simplified-issue version uses health questions and automated underwriting, while the Guaranteed Issue version requires no health questions and no medical exam ^[13].

For a buyer with well-managed diabetes who wants a level death benefit from day one, the simplified-issue product is the relevant plan. For a buyer whose diabetes, complications, or other conditions would block health questions, Guaranteed Issue is the fallback. The two products are not interchangeable: the simplified-issue version can pay the full death benefit immediately if the applicant qualifies, while Guaranteed Issue imposes a two-year limited-benefit period ^[15].

Coverage amounts differ by design. SimpliNow Legacy is described as offering $5,000–$35,000 for the level design and $5,000–$25,000 for the graded design, while Guaranteed Issue Whole Life is described as $5,000–$25,000 ^[11]. That range covers the buyer's $15,000–$25,000 target, but the platforms disagreed on whether the full target amount is reliably available in every state and product version, and one platform noted a combined SIWL-plus-GIWL cap of $25,000 graded or $35,000 level ^[11].

The issuing insurer is identified on Corebridge's final expense page as American General life insurance Company, with a New York issuer exception noted ^[10]. Buyers should confirm the exact issuing entity on the policy illustration rather than relying on the AIG brand name.

What the AI Platforms Agreed About

Questions This Section Answers

• What do AI platforms agree on about AIG for final expense insurance for people with diabetes?
• Does AIG offer a no-exam final expense option for diabetics?

The platforms agreed on four points. First, AIG's relevant business for this use case is Corebridge Financial, and the direct-to-consumer life insurance business formerly called AIG Direct was renamed Corebridge Direct in July 2024 ^[17]. Second, the relevant products are permanent whole life, not term, which matches the buyer's request for permanent final expense coverage ^[19].

Third, the platforms agreed that AIG/Corebridge offers both a simplified-issue path and a Guaranteed Issue path, and that Guaranteed Issue removes health questions entirely ^[21]. Fourth, they agreed that Guaranteed Issue carries a two-year limited-benefit period in which a natural-cause death returns premiums plus a stated percentage rather than the full face amount ^[24].

The platforms also broadly agreed that no medical exam is required for either path, which is a practical advantage for older applicants ^[26]. Agreement on these structural facts does not establish that AIG's underwriting is favorable for diabetes, and no platform supplied verified diabetes-specific approval data.

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Where do AI platforms disagree about AIG's diabetes underwriting for final expense coverage?
• Is AIG's diabetes underwriting actually favorable, or is that claim unverified?

The sharpest disagreement was whether AIG's simplified-issue underwriting is genuinely favorable for diabetes. Anthropic reported specific underwriting criteria: A1C ≤8.6% qualifies for a level benefit if the applicant is not on insulin, A1C 8.7–9.9% results in a graded offer, A1C ≥10% is declined, and amputation due to diabetes or diabetes-related hospitalization in the last 24 months is an automatic decline ^[28]. That is the most detailed diabetes-specific evidence in the study, but it comes from a platform-reported underwriting guideline document rather than an independently verified carrier rate table.

Other platforms treated the same question as unresolved. OpenAI stated that public product materials do not state whether type 1 or type 2 diabetes, A1C, insulin use, complications, or related medications receive preferred, standard, rated, or declined treatment ^[29]. Deepseek described diabetes underwriting as case-specific and not guaranteed ^[30]. Grok noted that specific underwriting guidelines for diabetes under AIG/Corebridge SIWL were not detailed in the public sources it checked ^[31]. Kimi stated that exact A1C thresholds and complication rules are not transparent ^[32].

A second disagreement concerned whether AIG competes in the simplified-issue final expense market at all. One independent review stated that AIG/Corebridge does not typically compete in the simplified-issue final expense market and specializes instead in fully underwritten high-face-value or guaranteed-issue policies ^[33]. That conflicts with platforms that described a functioning simplified-issue path with published coverage limits ^[35]. The conflict is unresolved in the supplied evidence.

A third uncertainty is product naming. Sources alternate between "AIG," "AIG Corebridge," "Corebridge SIWL Direct," and "Corebridge Final Expense Whole Life," and it is unclear whether these are identical products, rate-equivalent successors, or different offerings ^[32]. A fourth is corporate stability: one independent review stated that 2026 corporate transactions prompted rating agencies to place Corebridge's financial strength rating under review, while noting its current AM Best rating remained A (Excellent) ^[36]. That claim is platform-reported and should be verified directly with the carrier or a rating agency.

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What features does AIG's Corebridge final expense policy offer a diabetic buyer who needs $15,000 to $25,000 of coverage?
• Does AIG's final expense policy include living benefits or a limited-pay option for a senior with diabetes?

The features most relevant to this buyer are the no-exam application, the two underwriting paths, level premiums, and included living benefits. Corebridge states that the final expense application can be completed without a medical exam and that some underwriting decisions may be made quickly ^[37]. Anthropic reported that SimpliNow Legacy provides instant automated decisions within minutes with no tele-interviews and no attending physician statements ^[39].

Premiums are described as level and guaranteed not to increase, and a limited-pay feature is reported to stop premium payments at a maximum payment age while coverage continues to age 100 ^[41]. The policy is reported to mature or endow at age 100 ^[41]. Chronic illness and terminal illness accelerated death benefit riders are described as included at no extra cost, though use can reduce the death benefit or policy values and rider terms may vary by state ^[37].

Two structural limits matter for this use case. First, the Guaranteed Issue version pays a limited benefit during the first two policy years, described as 110% of premiums paid if death occurs in that period ^[40]. Second, no policy exchanges or conversions are permitted, and face amount increases or decreases are not allowed after issue ^[41]. A buyer who expects their diabetes control or coverage needs to change should weigh that inflexibility.

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does AIG's Corebridge final expense insurance cost per month for a senior with diabetes?
• What fees and contract terms apply to AIG's Guaranteed Issue Whole Life policy?

No platform supplied a verified diabetes-specific premium schedule for $15,000–$25,000 of coverage. OpenAI, deepseek, grok, and perplexity all reported low pricing confidence and stated that a personalized quote is required ^[45]. Kimi and google reported moderate-to-high confidence using example rates rather than verified carrier tables.

The available cost data is example-based. Kimi reported SIWL Direct level rates of $27 female / $34 male per month for $10,000 at age 50, rising to $107 female / $153 male at age 80, and stated that diabetic applicants at level tiers typically pay 10–30% more than non-diabetic applicants ^[49]. Google reported Guaranteed Issue examples of about $22/month for a 50-year-old female and $32/month for a 50-year-old male for $5,000 of coverage, and roughly $48–$65/month for a 65-year-old buyer at $10,000 ^[50]. These figures are platform-reported and were not independently verified.

Known fees include an annual policy fee reported at $36 for the level design and $12 for the graded design ^[51]. Administrative fees apply when chronic or terminal illness benefits are activated, but the amounts were not disclosed in the reviewed materials ^[51]. Policy loan interest was reported at an 8% effective annual rate ^[51]. Corebridge also warns that cumulative premiums may exceed the policy's face amount in some circumstances ^[45].

Contract terms reported across platforms include a 31-day grace period in most states and 60 days in California, a 10-day free look for the level death benefit and 30 days for the graded death benefit, and no exchanges or conversions ^[51]. Guaranteed Issue premiums were described as 40–80% above level rates ^[49]. All of these terms are platform-reported and should be confirmed in the policy contract.

Best Suited For

Questions This Section Answers

• Who is AIG's Corebridge final expense insurance best suited for among seniors with diabetes?
• Is AIG a good choice for a diabetic who cannot pass health questions on other final expense policies?

AIG/Corebridge is best suited for a senior with diabetes who wants permanent coverage in the $15,000–$25,000 range and values either a fast simplified-issue decision or a guaranteed-acceptance fallback. The platforms most often described it as a fit for applicants with stable, well-managed diabetes who may qualify for a level death benefit, and for applicants whose complications or health history make health questions a barrier ^[52].

It is also suited to buyers who prefer no medical exam and predictable level premiums, and to those who want living benefits included rather than sold as a paid rider ^[55]. Buyers already comparing Corebridge through an independent agent or broker were also named as a natural fit ^[57].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose AIG for final expense insurance for people with diabetes?
• Is AIG a poor choice for a diabetic who wants the lowest possible premium?

AIG/Corebridge is probably not the best choice for a buyer with well-controlled diabetes who wants the absolute lowest premium and can qualify for a fully underwritten or more competitive simplified-issue policy elsewhere. Multiple platforms stated that AIG is not the cheapest option for the healthiest applicants and named Mutual of Omaha, Aflac, Americo, Foresters, and Gerber as comparison points ^[58].

It is also a weaker fit for buyers who need the full $15,000–$25,000 death benefit immediately and cannot accept a two-year limited-benefit period, since that applies to Guaranteed Issue and to graded simplified-issue offers ^[61]. Buyers who require publicly posted diabetes-specific eligibility rules or transparent online pricing before applying are also poorly served, because no platform found verified public rate tables ^[63]. Applicants outside the reported age 50–80 range, and New York residents seeking the simplified-issue product, were also flagged as poor fits ^[65].

When Another Option May Be Better

Questions This Section Answers

• When is another carrier a better choice than AIG for a senior with diabetes seeking final expense coverage?
• What should a diabetic buyer compare against AIG before buying final expense insurance?

Another option may be better when the applicant's diabetes is well controlled enough to qualify for a level, day-one benefit at a lower premium from a carrier that specializes in simplified-issue final expense. Platforms repeatedly named Mutual of Omaha's Living Promise Level, Aflac, Americo, Foresters, and Gerber as alternatives worth quoting ^[67].

Another option may also be better when the buyer needs more than $25,000 in immediate coverage from a single policy, since the Guaranteed Issue cap and the combined SIWL-plus-GIWL cap limit stacking ^[70]. Buyers who want fully published underwriting rules and rates before applying, or who want to avoid the corporate restructuring uncertainty around the AIG-to-Corebridge transition, were also directed elsewhere ^[72].

For buyers who want to see how AIG compares against the full field, the Final Expense Insurance for People With Diabetes consensus index ranks every carrier that qualified in this study.

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with AIG or Corebridge before signing a final expense contract?
• Which diabetes details does AIG need to determine whether simplified issue or Guaranteed Issue applies?

Before buying, confirm the applicant's current A1C and how it was measured, because the reported simplified-issue thresholds turn on that number ^[74]. Confirm whether the applicant uses insulin, since insulin use with a higher A1C was reported to shift the offer to a graded benefit ^[74]. Confirm whether there has been a diabetes-related hospitalization in the last 24 months or any amputation, both of which were reported as automatic declines ^[74].

Also confirm the exact issuing insurer on the policy illustration, whether $15,000, $20,000, or $25,000 is available at the applicant's age and state, whether the policy pays the full death benefit from day one or uses a two-year graded provision, and the exact monthly, quarterly, semiannual, and annual premiums ^[75]. Confirm the grace period, reinstatement rules, surrender charges, loan interest, and any administrative fee tied to living-benefit activation ^[76]. Finally, confirm state availability, since the simplified-issue product was reported as not approved in New York ^[76].

Final AI Consensus Verdict

AIG is a mixed-to-good fit for a senior with diabetes seeking $15,000–$25,000 of permanent final expense coverage, and it should be treated as one quote to compare rather than a confirmed diabetes-specialist choice. Five of seven platforms named it in the ranking stage, and platform fit ratings split four "good" to three "mixed." The strongest case for AIG is the dual structure: a simplified-issue path that may accept well-managed diabetes with a level death benefit, plus a Guaranteed Issue fallback with no health questions ^[77].

The strongest case against relying on it is evidentiary. No platform produced verified diabetes-specific approval data or public rate tables, one independent review stated that AIG/Corebridge does not typically compete in the simplified-issue final expense market ^[80], and the Guaranteed Issue path carries a two-year limited-benefit period ^[81]. Buyers with well-controlled diabetes should quote AIG alongside Mutual of Omaha, Aflac, and other final expense specialists before deciding.

How This Review Was Produced

This review was produced from seven AI platform responses collected for a single buyer prompt: a senior with diabetes seeking approximately $15,000–$25,000 of permanent final expense life insurance from a carrier whose underwriting may be reasonably favorable for well-managed or otherwise insurable diabetes. The study date is 2026-09-22. Five of the seven platforms named AIG during ranking discovery, and all seven supplied fit-research responses that were used to build the findings above.

Platform fit ratings were recorded as supplied: anthropic, google, kimi, and perplexity rated AIG a "good" fit; deepseek, grok, and openai rated it "mixed." Product names, coverage limits, underwriting criteria, and pricing were taken from the platform responses and their cited sources without independent verification. Where platforms conflicted, both positions are reported rather than resolved.

Methodology Limitations

Several limitations apply. Platform-reported research dates differ from the authoritative run date of 2026-09-22: anthropic reported 2026-01-15, deepseek reported 2026-06-01, and google, grok, kimi, openai, and perplexity reported 2026-09-23. Those dates are provenance metadata and do not independently prove freshness.

All included platforms evaluated fit, but the platform-mention count reflects only platforms that named AIG during ranking discovery. The supplied URLs were collected from platform responses and were not independently validated. Citations are platform-reported evidence, not independently verified facts, and claims from platforms without search enabled require explicit verification before being treated as current.

The deterministic identity audit noted that official-site retrieval failed for one or more mentions, that one or more fetched domains were not corroborated by brand-name or site-identity metadata, and that company-name variants were collapsed onto one canonical brand before minimum-mention qualification. The official-page excerpts retrieved for AIG were marked retrieved-not-verified and contained only corporate and terms-of-use content, not product or pricing details.

Material conflicts remain unresolved: whether AIG competes in the simplified-issue final expense market, whether the various product names refer to the same offering, the exact A1C and complication thresholds for level versus graded versus decline, and whether the requested $15,000–$25,000 amount is available in every state and product version. No platform supplied verified diabetes-specific premium data, and no personal testing, customer experience, or independent verification was performed for this review.